The selective estrogen receptor modulator raloxifene lowers the risk of intima-media thickness (IMT) progression in postmenopausal women by about 40%.
The selective estrogen receptor modulator raloxifene lowers the risk of intima-media thickness (IMT) progression in postmenopausal women by about 40%, according to the results of a recent prospective study.
The study involved 155 healthy postmenopausal women who received either raloxifene 60 mg/d or placebo for 18 months.
Not only was the progression slope of carotid IMT more favorable in the raloxifene group than in the placebo group (0.0112 mm/18 mo vs. 0.0857 mm/18 mo, respectively; P<0.004), but the women taking raloxifene experienced significant decreases in plasma triglycerides (P<0.02), low-density lipoprotein cholesterol (P<0.02), soluble forms of intercellular adhesion molecule-1 (P<0.005) and vascular cell adhesion molecule-1 (P<0.04), E-selectin (P<0.02), interleukin-6 (P<0.005), tumor necrosis factor α (P<0.005) levels, and in the homeostatic model assessment index (P<0.005), and a significant increase in plasma adiponectin levels (P<0.001).
Get the latest clinical updates, case studies, and expert commentary in obstetric and gynecologic care. Sign up now to stay informed.
Trimethoprim–sulfamethoxazole not found to increase infant birth weight in HIV cases
July 9th 2025A recent randomized trial found no significant improvement in birth weight or key birth outcomes from antenatal trimethoprim–sulfamethoxazole prophylaxis in human immunodeficiency virus-positive pregnant women.
Read More